[Cerebral toxoplasmosis in HIV infected patients intolerant of cotrimoxazole].
Using results of a multicentric randomized prospective trial of primary prophylaxis of Pneumocystis carinii pneumonia in HIV-infected patients which compared sulfamethoxazole-trimethoprim and pentamidine isethionate, the risk to develop cerebral toxoplasmosis was analyzed in the two assigned groups and in the groups of patients who stopped sulfamethoxazole-trimethoprim prophylaxis. The risk to develop cerebral toxoplasmosis appeared significantly higher in the group of patients who stopped sulfamethoxazole-trimethoprim consecutively to cutaneous hypersensitivity.
Rabaud
C
C
Service de Maladies Infectieuses et Tropicales, CHU, Nancy.
May
T
T
Beuscart
C
C
Reynes
J
J
Leport
C
C
Canton
P
P
D017088:AIDS-Related Opportunistic Infections / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality; D003875:Drug Eruptions / Q000209:etiology* / Q000517:prevention & control; D004359:Drug Therapy, Combination; D005500:Follow-Up Studies; D006801:Humans; D015337:Multicenter Studies as Topic; D010419:Pentamidine / Q000008:administration & dosage / Q000009:adverse effects; D011020:Pneumonia, Pneumocystis / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality; D011336:Probability; D011446:Prospective Studies; D016032:Randomized Controlled Trials as Topic; D012306:Risk; D015996:Survival Rate; D016781:Toxoplasmosis, Cerebral / Q000175:diagnosis / Q000209:etiology* / Q000401:mortality / Q000517:prevention & control; D015662:Trimethoprim, Sulfamethoxazole Drug Combination / Q000008:administration & dosage / Q000009:adverse effects*
D010419:Pentamidine; D015662:Trimethoprim, Sulfamethoxazole Drug Combination